Crispr Therapeutics AG (CRSP) financial statements
Crispr Therapeutics AG reported revenue of $4M in fiscal 2025, down 4.2% a year over 9 years.
Net income was -$582M and the operating margin -18933.6%, against -1319.3% in 2016.
Free cash flow was -$346M.
The diluted share count rose 634% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Crispr Therapeutics AG's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $41M | $3M | $290M | $719,000 | $915M | $1M | $371M | $37M | $4M |
| Research and development | $42M | $70M | $114M | $179M | $221M | $341M | $462M | $387M | $310M | $285M |
| Selling, general and admin | $31M | $36M | $48M | $63M | $86M | $100M | $102M | $76M | $73M | $74M |
| Operating income | -$68M | -$65M | -$159M | $47M | -$354M | $374M | -$673M | -$223M | -$467M | -$665M |
| Pre-tax income | -$23M | -$67M | -$164M | $67M | -$348M | $380M | -$650M | -$151M | -$363M | -$578M |
| Income tax | $484,000 | $2M | $553,000 | $448,000 | $809,000 | $2M | -$325,000 | $3M | $4M | $4M |
| Net income | -$23M | -$68M | -$165M | $67M | -$349M | $378M | -$650M | -$154M | -$366M | -$582M |
| EPS (diluted) | -$1.89 | -$1.71 | -$3.44 | $1.17 | -$5.29 | $4.70 | -$8.36 | -$1.94 | -$4.34 | -$6.47 |
| Diluted shares | 12M | 40M | 48M | 57M | 66M | 80M | 78M | 79M | 84M | 90M |
| Operating margin | -1319.3% | -157.7% | -5087.8% | 16.1% | -49295.5% | 40.8% | -56190.4% | -60.0% | -1250.4% | -18933.6% |
| Net margin | -448.8% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.3% | -54271.7% | -41.4% | -981.5% | -16569.8% |
Balance sheet
Fiscal years, from Crispr Therapeutics AG's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $316M | $240M | $457M | $944M | $1.7B | $2.4B | $1.8B | $1.7B | $1.9B | $2.0B |
| Receivables | $3M | $3M | $88,000 | $99,000 | $144,000 | $305,000 | $0 | $200M | $25M | $0 |
| Total current assets | $320M | $248M | $466M | $988M | $1.7B | $2.4B | $1.9B | $1.9B | $1.9B | $2.0B |
| Property, plant and equipment | $21M | $19M | $18M | $31M | $42M | $138M | $164M | $152M | $134M | $116M |
| Total assets | $345M | $271M | $489M | $1.1B | $1.8B | $2.8B | $2.2B | $2.2B | $2.2B | $2.3B |
| Total current liabilities | $22M | $15M | $28M | $57M | $94M | $120M | $121M | $109M | $88M | $149M |
| Total liabilities | $112M | $84M | $97M | $127M | $164M | $352M | $368M | $347M | $310M | $343M |
| Shareholders' equity | $233M | $188M | $392M | $939M | $1.7B | $2.4B | $1.9B | $1.9B | $1.9B | $1.9B |
| Net debt | -$316M | -$240M | -$457M | -$944M | -$1.2B | -$923M | -$212M | -$389M | -$298M | -$348M |
Cash flow
Fiscal years, from Crispr Therapeutics AG's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$53M | -$70M | -$96M | $57M | -$238M | $539M | -$496M | -$260M | -$143M | -$345M |
| Capital spending | $3M | $8M | $3M | $7M | $18M | $82M | $37M | $9M | $2M | $914,000 |
| Free cash flow | -$56M | -$78M | -$99M | $50M | -$257M | $457M | -$533M | -$270M | -$145M | -$346M |
| Stock-based compensation | $11M | $19M | $35M | $44M | $66M | $102M | $98M | $81M | $87M | $72M |
| Share buybacks (net) | — | — | -$57,000 | — | — | — | — | — | — | — |
| Free cash flow margin | -1082.0% | -190.0% | -3169.4% | 17.3% | -35705.7% | 50.0% | -44484.9% | -72.7% | -387.7% | -9855.5% |
Questions
What was Crispr Therapeutics AG's revenue in 2025?
$4M in fiscal 2025, from its 10-K filing.
How much free cash flow does Crispr Therapeutics AG generate?
-$346M in fiscal 2025 (operating cash flow minus capital spending).
From Crispr Therapeutics AG's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.